论文部分内容阅读
雌激素受体α(ERα)36是相对分子质量为36×103的ERα的一种亚型。它缺失转录活性区1(AF-1)和转录活性区2(AF-2),在生物学功能上与ERα66有很大不同。ERα36主要位于细胞膜和细胞质中,主要参与膜介导的非基因组信号通路。它能抑制ERα66介导的传统基因组信号通路,引起不同蛋白的层级磷酸化反应,增加乳腺癌和子宫内膜癌细胞及其干细胞的耐药性、迁移能力和浸润能力。研究显示ERα36与乳腺癌采用他莫昔芬治疗耐药有密切关系。对ERα36的深入研究有助于深化乳腺癌发生发展的理论知识,为内分泌治疗药物选择提供可能的理论依据。
Estrogen receptor alpha (ERa) 36 is a subtype of ERa with a relative molecular mass of 36x103. It lacks the transcriptional activity region 1 (AF-1) and the transcriptional activation region 2 (AF-2), and is very different in biological function from ERα66. ERα36 mainly in the cell membrane and cytoplasm, mainly involved in membrane-mediated non-genomic signaling pathway. It can inhibit the ERα66-mediated traditional genomic signaling pathway, causing hierarchical phosphorylation of different proteins and increasing the resistance, migration and invasion ability of breast and endometrial cancer cells and their stem cells. Studies have shown that ERα36 and breast cancer using tamoxifen resistance are closely related. In-depth study of ERα36 will help deepen the theoretical knowledge of the development of breast cancer and provide a possible theoretical basis for the choice of endocrine therapy drugs.